Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis

Rheumatology International

Volumn 36, Issue 6, 2016, Pages 837-844

  Lee, Young Ho ^a   Bae, Sang Cheol ^b  

^a College of Medicine   (South Korea)

^b Hanyang University Medical Center   (South Korea)

Author keywords

FCGR polymorphism; PTPRC; Responsiveness; Rheumatoid arthritis; TNF blockers

Indexed keywords

ADALIMUMAB; ETANERCEPT; FC RECEPTOR IIA; INFLIXIMAB; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE C; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CD45 ANTIGEN; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; PTPRC PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ALLELE; ARTICLE; DNA POLYMORPHISM; GENOTYPE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; ODDS RATIO; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; RISK FACTOR; TREATMENT OUTCOME;

ADALIMUMAB; ANTIGENS, CD45; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ETANERCEPT; GENE FREQUENCY; GENOTYPE; HUMANS; INFLIXIMAB; ODDS RATIO; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84963704606     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-016-3476-5     Document Type: Article

References (35)

1. Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322(18):1277–1289
2. Choi SJ, Rho YH, Ji JD, Song GG, Lee YH (2006) Genome scan meta-analysis of rheumatoid arthritis. Rheumatology (Oxford) 45(2):166–170
3. Brennan FM, Maini RN, Feldmann M (1992) TNF alpha–a pivotal role in rheumatoid arthritis? Br J Rheumatol 31(5):293–298
4. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C et al (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70(2):266–271
5. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C et al (2009) Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 41(12):1313–1318
6. Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7(11):833–846
7. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum Arthritis Care Res 62(7):1849–1861
8. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–290
9. Chai L, Song YQ, Leung WK (2012) Genetic polymorphism studies in periodontitis and Fcgamma receptors. J Periodontal Res 47(3):273–285
10. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131(2):308–316
11. Avila-Pedretti G, Tornero J, Fernández-Nebro A, Blanco F, González-Alvaro I, Cañete JD et al (2015) Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS One 10(4):e0122088
12. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR et al (2009) Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45(2):124–131
13. Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Canete JD, Raya E, Magro-Checa C, et al (2016) Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J 16(2):137–140
14. Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F et al (2013) Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS One 8(9):e74375
15. Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD et al (2012) Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64(3):665–670
16. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62(7):1849–1861
17. Davila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW et al (2015) FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics 16(4):373–381
18. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V et al (2014) Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 24(5):238–245
19. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R et al (2009) Influence of variants of Fc gamma receptors IIA and IIIA on the American College of rheumatology and european league against rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68(10):1547–1552
20. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27(9):827–833
21. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2011) Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 38(6):3643–3651
22. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 37(1):227–234
23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558
24. Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315(7121):1533–1537
25. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
26. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634
27. Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21:107–137
28. Stanford SM, Rapini N, Bottini N (2012) Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity. Immunology 137(1):1–19
29. Cooper DN (2010) Functional intronic polymorphisms: buried treasure awaiting discovery within our genes. Hum Genomics 4(5):284–288
30. Choi SJ, Rho YH, Ji JD, Song GG, Lee YH (2006) Genome scan meta-analysis of rheumatoid arthritis. Rheumatology 45(2):166–170
31. Tak PP (2012) A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 51(4):600–609
32. Su K, Wu J, Edberg JC, McKenzie SE, Kimberly RP (2002) Genomic organization of classical human low-affinity Fcgamma receptor genes. Genes Immun 3(Suppl 1):S51–S56
33. Sanders LA, Feldman RG, Voorhorst-Ogink MM, de Haas M, Rijkers GT, Capel PJ et al (1995) Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 63(1):73–81
34. Nimmerjahn F, Ravetch JV (2008) Fcγ receptors as regulators of immune responses. Nat Rev Immunol 8(1):34–47
35. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y et al (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52(1):61–72